Stroke and stroke care in China: huge burden, significant workload, and a national priority.

At the same time as the world recognizes the rapid economic development in China, Chinese healthcare system has also had significant improvement. However, this nation of 1.4 billion faces tough challenges in treating stroke, the leading cause of death in China. The recently completed Chinese National Stroke Registry has provided new information on the status of stroke epidemiology, diagnosis, management, and prevention strategies in China. In this article, we summarized these new findings, described the effort of providing and improving stroke care, and illustrated the challenges in risk factor modification and secondary stroke prevention. Well-designed epidemiological surveys and clinical trials for stroke prevention and management are still urgently needed in China.

[1]  S Claiborne Johnston,et al.  Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling , 2009, The Lancet Neurology.

[2]  Tsung O Cheng,et al.  Stroke in china. , 2004, Stroke.

[3]  Yilong Wang,et al.  Antithrombotic management of ischaemic stroke and transient ischaemic attack in China: A consecutive cross‐sectional survey , 2010, Clinical and experimental pharmacology & physiology.

[4]  W. D’Souza,et al.  An Epidemiological Survey of Stroke in Lhasa, Tibet, China , 2010, Stroke.

[5]  Liping Liu,et al.  The China National Stroke Registry for Patients with Acute Cerebrovascular Events: Design, Rationale, and Baseline Patient Characteristics , 2011, International journal of stroke : official journal of the International Stroke Society.

[6]  S. Yusuf,et al.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study , 2010, The Lancet.

[7]  Hao Li,et al.  Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China: Analysis of the Results From the Chinese National Stroke Registry (CNSR) , 2011, Stroke.

[8]  Ming Liu,et al.  Stroke in China: epidemiology, prevention, and management strategies , 2007, The Lancet Neurology.

[9]  S. Johnston,et al.  Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. , 2010, American heart journal.

[10]  Dong Zhao,et al.  Epidemiological Transition of Stroke in China: Twenty-One–Year Observational Study From the Sino-MONICA-Beijing Project , 2008, Stroke.